Literature DB >> 25400283

Blood plasma lipidomic signature of epicardial fat in healthy obese women.

Max Scherer1, Ivan Montoliu, Salah D Qanadli, Sebastiano Collino, Serge Rezzi, Martin Kussmann, Vittorio Giusti, François-Pierre J Martin.   

Abstract

OBJECTIVES: A lipidomic approach was employed in a clinically well-defined cohort of healthy obese women to explore blood lipidome phenotype ascribed to body fat deposition, with emphasis on epicardial adipose tissue (EAT).
METHODS: The present investigation delivered a lipidomics signature of epicardial adiposity under healthy clinical conditions using a cohort of 40 obese females (age: 25-45 years, BMI: 28-40 kg/m(2) ) not showing any metabolic disease traits. Lipidomics analysis of blood plasma was employed in combination with in vivo quantitation of mediastinal fat depots by computerized tomography.
RESULTS: All cardiac fat depots correlated to indicators of hepatic dysfunctions (ALAT and ASAT), which describe physiological connections between hepatic and cardiac steatosis. Plasma lipidomics encompassed overall levels of lipid classes, fatty acid profiles, and individual lipid species. EAT and visceral fat associated with diacylglycerols (DAG), triglycerides, and distinct phospholipid and sphingolipid species. A pattern of DAG and phosphoglycerols was specific to EAT.
CONCLUSIONS: Human blood plasma lipidomics appears to be a promising clinical and potentially diagnostic readout for patient stratification and monitoring. Association of blood lipidomics signature to regio-specific mediastinal and visceral adiposity under healthy clinical conditions may help provide more biological insights into obese patient stratification for cardiovascular disease risks.
© 2014 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25400283     DOI: 10.1002/oby.20925

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  6 in total

1.  Plasma lipidome patterns associated with cardiovascular risk in the PREDIMED trial: A case-cohort study.

Authors:  Cristina Razquin; Liming Liang; Estefanía Toledo; Clary B Clish; Miguel Ruiz-Canela; Yan Zheng; Dong D Wang; Dolores Corella; Olga Castaner; Emilio Ros; Fernando Aros; Enrique Gomez-Gracia; Miquel Fiol; José Manuel Santos-Lozano; Marta Guasch-Ferre; Lluis Serra-Majem; Aleix Sala-Vila; Pilar Buil-Cosiales; Monica Bullo; Montserrat Fito; Olga Portoles; Ramon Estruch; Jordi Salas-Salvado; Frank B Hu; Miguel A Martinez-Gonzalez
Journal:  Int J Cardiol       Date:  2018-02-15       Impact factor: 4.164

2.  Analysis of lipid adsorption on nanoparticles by nanoflow liquid chromatography-tandem mass spectrometry.

Authors:  Ju Yong Lee; Hua Wang; Georgios Pyrgiotakis; Glen M DeLoid; Zhenyuan Zhang; Juan Beltran-Huarac; Philip Demokritou; Wenwan Zhong
Journal:  Anal Bioanal Chem       Date:  2018-05-30       Impact factor: 4.142

Review 3.  Lipidomics in the Study of Hypertension in Metabolic Syndrome.

Authors:  Hemant Kulkarni; Manju Mamtani; John Blangero; Joanne E Curran
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

Review 4.  Physiological Changes and Pathological Pain Associated with Sedentary Lifestyle-Induced Body Systems Fat Accumulation and Their Modulation by Physical Exercise.

Authors:  Enrique Verdú; Judit Homs; Pere Boadas-Vaello
Journal:  Int J Environ Res Public Health       Date:  2021-12-17       Impact factor: 3.390

Review 5.  Longitudinal omics modeling and integration in clinical metabonomics research: challenges in childhood metabolic health research.

Authors:  Peter Sperisen; Ornella Cominetti; François-Pierre J Martin
Journal:  Front Mol Biosci       Date:  2015-08-05

6.  Metabolomics: a search for biomarkers of visceral fat and liver fat content.

Authors:  Sebastiaan Boone; Dennis Mook-Kanamori; Frits Rosendaal; Martin den Heijer; Hildo Lamb; Albert de Roos; Saskia le Cessie; Ko Willems van Dijk; Renée de Mutsert
Journal:  Metabolomics       Date:  2019-10-05       Impact factor: 4.290

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.